Table 2.

Characteristics of the study population stratified by the occurrence of major adverse cardiac and cerebrovascular events (MACCE).

		Studied population (N = 100)	MACCE-group (N = 13)	No MACCE-group (N = 87)	p-value
Age (years)		64.9 $\pm$ 12.6	70.3 $\pm$ 17.9	64.1 $\pm$ 11.5	0.099
BMI (kg/$m^2$)		27.4 $\pm$ 5.3	25.8 $\pm$ 4.3	27.6 $\pm$ 5.4	0.267
LVEF (%)		52.3 $\pm$ 10.4	48 $\pm$ 10.9	52.9 $\pm$ 10.3	0.116
Women (n, %)		18 (18)	4 (30.8)	14 (16.1)	0.243
Dyslipidemia (n, %)		52 (52)	2 (15.4)	45 (51.7)	0.886
Diabetes mellitus (n, %)		25 (25)	2 (15.4)	23 (26.4)	0.508
Hypertension (n, %)		62 (62)	9 (69.2)	53 (60.9)	0.761
Smoking (n, %)		28 (28)	3 (35.7)	25 (28.7)	0.171
Chronic kidney disease (n, %)		34 (34)	7 (53.8)	27 (31.4)	0.128
Acute coronary syndrome as initial presentation (n, %)		32 (32)	5 (38.5)	27 (31)	0.533
Significant CAD (n, %)		78 (78)	11 (84.6)	67 (77)	0.727
Type of CAA (n, %)					0.357
	Fusiform	54 (50)	9 (60)	45 (48.4)
	Saccular	54 (50)	6 (40)	48 (51.6)
Longitudinal aneurysm diameter (mm)		10.4 $\pm$ 6.4	13.5 $\pm$ 8.3	9.98 $\pm$ 6	0.074
Transverse aneurysm diameter (mm)		7.2 $\pm$ 2.2	7.2 $\pm$ 1.3	7.23 $\pm$ 2.3	0.974
Giant CAA (n, %)		21 (19.4)	2 (12.5)	19 (20.6)	1
Therapeutic strategy (n, %)					1
	Medical	47 (47)	6 (46.2)	41 (47.1)
	PCI	42 (42)	6 (46.2)	36 (41.4)
	CABG	11 (11)	1 (7.7)	10 (11.5)
Conservative approach (n, %)		47 (47)	6 (46.2)	41 (47.1)	0.948
Invasive approach (n, %)		53 (53)	7 (53.8)	46 (52.9)
Anti-thrombotic treatment (n, %)					0.170
	None	5 (5)	0 (0)	5 (5.7)
	Aspirin or P2Y12-	40 (40)	7 (53.8)	33 (38)
	Dual anti-platelet	30 (30)	1 (7.7)	29 (33.3)
	Oral anticoagulant	25 (25)	5 (38.5)	20 (23)

*MACCE, major adverse cardiac and cerebrovascular events; BMI, body mass index; LVEF, left ventricular ejection fraction; CAD, coronary artery disease; CAA, coronary artery aneurysm.